SOUTH SAN FRANCISCO, Calif.,
April 25, 2017 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today
announced that it will report its first quarter 2017 financial
results after market close on Tuesday, May
2, 2017. Rigel senior management will follow the
announcement with a live conference call and webcast at
5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial
results.
Participants can access the live conference call by dialing
855-892-1489 (domestic) or 720-634-2939 (international) and using
the Conference ID number 11028280. The conference call will
also be webcast live and can be accessed from Rigel's website at
www.rigel.com. The webcast will be archived and
available for replay after the call via the Rigel website.
About Rigel (www.rigel.com)
Rigel
Pharmaceuticals, Inc. is a clinical-stage biotechnology company
dedicated to the discovery and development of novel, targeted drugs
in the therapeutic areas of immunology, oncology and
immuno-oncology. Rigel's pioneering research focuses on signaling
pathways that are critical to disease mechanisms. The company's
current clinical programs include clinical trials of fostamatinib,
an oral spleen tyrosine kinase (SYK) inhibitor, in a number of
indications. The company submitted a NDA to the FDA for
fostamatinib in patients with chronic and persistent immune
thrombocytopenia (ITP) in April 2017.
Rigel is also conducting Phase 2 clinical trials with fostamatinib
in autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN).
In addition, Rigel has two oncology product candidates in
development with partners BerGenBio AS and Daiichi Sankyo.
Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
Media Contact: Jessica Daitch,
Inventiv Health PR Group
Phone: 917.816.6712
Email: Jessica.daitch@inventivhealth.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2017-financial-results-300444737.html
SOURCE Rigel Pharmaceuticals, Inc.